Evolva gains major contract from USA's Defense Threat Reduction Agency  

The Danish biotech company has entered a USD 26.7 m contract with DTRA for the discovery and development of drugs which can strengthen the immune system
Danish biotech company Evolva has entered a USD 26.7 m (DKK 155.2 m) contract with the Defense Threat Reduction Agency (DTRA) in the US for the discovery and development of drugs which can strengthen the immune system, in particular against biological terror attacks. The contract will almost double the firm's research staff who are located in India, Switzerland and Denmark.
Neil Goldsmith, managing director of Evolva says: "The DTRA award shows the potential applicability of our genetic chemistry technologies to a further therapeutic area. It allows us to build a pipeline of compounds with immunomodulatory and other effects that can assist humans to resist pathogens and other diseases, including as yet uncharacterised threats."
Over the next five years, Evolva will collaborate with the Swedish company Isconova to find and develop potential drugs. Initially test systems to identify potential drugs will be developed. DTRA owns the rights to potential products, while Evolva has the rights to the technological platform and can exploit it commercially if the research delivers positive results. The news was reported by financial daily newspaper Børsen and in a press release from Evolva.
Link > Evolva  

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×